EUCTR2015-001547-37-Outside-EU/EEA进行中（未招募）不适用
A Phase I, double-blind, randomised, placebo controlled study to evaluate the reactogenicity and safety of a single oral dose of GlaxoSmithKline (GSK) Biologicals’ live attenuated liquid human rotavirus (HRV) vaccine in healthy children aged 2 to 6 years in China.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Subjects who the investigator believes that their parents/guardians (Legally acceptable representative) can and will comply with the requirements of the protocol should be enrolled in the study.
- •-A male or female subject of Chinese origin, between, and including, 2 and 6 years of age at the time of vaccination.
- •-Written informed consent obtained from the parent or legally acceptable representative of the subject.
- •-Healthy subjects as established by medical history and clinical examination before entering into the stud
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 50
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the study vaccine, or planned use during the study period.
- •-Chronic administration of immunosuppressants or other immune-modifying drugs six months prior to the vaccine dose.
- •-Planned administration/administration of a vaccine not foreseen by the study protocol within 14 days of the Human Rotavirus vaccine or placebo with the exception of the routine childhood vaccines. Routine childhood vaccines must not be administered on the same day as the Human Rotavirus vaccine or placebo.
- •-Administration of immunoglobulins and/or any blood products since birth within three months preceding the study vaccine or planned administration during the study period.
- •-Major congenital defects or serious chronic illness.
- •-Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- •-History of Intusussception or any chronic gastrointestinal disease that would predispose for Intusussception including any uncorrected congenital malformation of the gastrointestinal tract.
- •-History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- •-Acute disease at the time of enrolment.
- •-Gastroenteritis within 7 days preceding the study vaccine or placebo administration.
- •-Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product..
- •-Child in care.
研究者
相似试验
已完成
1 期
A phase I, randomised, double-blind, placebo controlled, dose ranging study to evaluate the safety, tolerability and pharmacokinetics of EMA401 following multiple oral dosing in healthy male subjects.Postherpetic NeuralgiaACTRN12609000489291Spinifex Pharmaceuticals Pty Ltd36
已完成
1 期
To determine the safety, tolerability, uptake and breakdown of single and multiple doses of AS012 in healthy subjects.CTRI/2019/08/020753Sun Pharmaceutical Industries Ltd SPI167
尚未招募
1 期
To evaluate the safety, tolerability and pharmacokinetics of single-dose and multiple-dose administration of MKP 10241CTRI/2021/09/036637Mankind Pharma Limited
已完成
不适用
A phase 1, double-blind, randomised, placebo-controlled multiple dose study investigating the immunopharmacology of EDP1815 with multiple formulationsNL-OMON49769Evelo Biosciences Inc.48
已完成
不适用
A phase 1, double-blind, randomised, placebo-controlled multiple dose study investigating the immunopharmacology of EDP1066 with multiple formulationsAuto immune diseases10027665NL-OMON48298Evelo Biosciences Inc.80